Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer

Durvalumab, an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody, is currently used in the maintenance therapy for patients with stage III non‐small cell lung cancer after platinum‐based chemoradiotherapy. A 69‐year‐old male with lung adenocarcinoma, clinical stage IIIA, was treated with chemorad...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Takehiro, Fukumitsu, Kensuke, Maeno, Ken, Fukuda, Satoshi, Onuki, Tomohiro, Kanemitsu, Yoshihiro, Oguri, Tetsuya, Niimi, Akio, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374598/
https://www.ncbi.nlm.nih.gov/pubmed/34457312
http://dx.doi.org/10.1002/rcr2.835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374598/
https://www.ncbi.nlm.nih.gov/pubmed/34457312
http://dx.doi.org/10.1002/rcr2.835

Ejemplares similares